Hemophilia B: understanding christmas Disease and New treatment Options

Hemophilia B, also known as Christmas disease, is a rare genetic bleeding disorder resulting from low levels of factor 9, a crucial blood protein for blood clotting. Unlike hemophilia A, which stems from a deficiency in factor 8, hemophilia B is less common and generally less severe.

Without sufficient factor 9, individuals with hemophilia B experience prolonged bleeding, even from minor injuries. The severity of the condition – mild, moderate, or severe – depends on the level of factor 9 present. Mild cases may only cause bruising and bleeding after trauma or surgery, while moderate to severe cases can lead to spontaneous bleeding into joints, muscles, and internal organs like the kidneys, stomach, and brain. Untreated hemophilia B can result in long-term joint problems and even brain hemorrhage.

Currently, ther is no cure for hemophilia B, but effective treatments are available to manage bleeding episodes and allow individuals to live relatively normal lives.

treatment to Increase Clotting Enzymes

A new treatment option, Hympavzi, recently approved by the U.S. Food and drug Administration (FDA) in October 2024, offers a novel approach. This medication works by reducing tissue factor pathway inhibitors – proteins that limit blood clotting – thereby boosting the bodyS production of thrombin, the enzyme responsible for initiating clot formation.Hympavzi is suitable for individuals age 12 and older with hemophilia A or B without neutralizing antibodies to factors 8 or 9, respectively, and is administered weekly via a prefilled auto-injection pen.

Factor 9 Replacement Therapy

The conventional treatment for hemophilia B is factor 9 replacement therapy. This involves infusing either plasma-derived factor concentrates or recombinant factor concentrates directly into the bloodstream to restore proper clotting function.

Hemophilia B Treatment: beyond Factor IX

About 3 in 100 people with hemophilia B develop an inhibitor – a type of antibody – to their treatment product. When this happens, the body stops accepting the factor concentrate as a normal part of the body, launching antibodies to destroy the foreign substances, according to the CDC.this can make it more challenging to stop a bleeding episode with medication. People with hemophilia are advised to get tested for inhibitors yearly so that serious health problems can be prevented. Inhibitors don’t necessarily cause symptoms, so a laboratory test is the only way to know whether a person has one. Treatment for an inhibitor is complex and requires specialized medical expertise. It’s also costly: The NBDF states that a person with an inhibitor usually has medical expenses of more than $1 million per year.

Othre Medications Used in Hemophilia B Treatment

Antifibrinolytics

In certain situations, drugs known as antifibrinolytics are used along with factor IX replacement to assist with blood clotting and reduce blood loss. Aminocaproic acid (Amicar) is a medication that prevents blood clots from breaking down.It is indeed frequently enough used for bleeding in the mouth or after a tooth has been removed, as it blocks a substance found in the saliva that breaks down clots. It may also be recommended before dental procedures. The drug can be taken orally as a pill or a liquid, or can be infused thru a vein. The MASAC notes in its treatment recommendations for hemophilia and other bleeding disorders that a dose of factor concentrate must be given first to form the clot, followed by aminocaproic acid to preserve the clot. Tranexamic acid (Lysteda) similarly slows blood clots from being broken down. It’s typically prescribed to treat heavy menstrual bleeding in girls and women age 12 and older to reduce menstrual blood loss.